These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20094009)

  • 1. Video microscope recording of the dynamic course of thrombosis and thrombolysis of the retinal vein in rabbits.
    Wu J; Zhou X; Hu Y; Zhang T; Ma Z; Li X; Su L; Wang J; Lin S
    Retina; 2010 Jun; 30(6):966-70. PubMed ID: 20094009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale of retinal endovascular fibrinolysis in the treatment of retinal vein occlusion: from experimental data to clinical application.
    Pournaras CJ; Petropoulos IK; Pournaras JA; Stangos AN; Gilodi N; Rungger-Brändle E
    Retina; 2012 Sep; 32(8):1566-73. PubMed ID: 22466460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs.
    Tameesh MK; Lakhanpal RR; Fujii GY; Javaheri M; Shelley TH; D'Anna S; Barnes AC; Margalit E; Farah M; De Juan E; Humayun MS
    Am J Ophthalmol; 2004 Nov; 138(5):829-39. PubMed ID: 15531319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
    Hattenbach LO; Friedrich Arndt C; Lerche R; Scharrer I; Baatz H; Margaron F; Richard G; Behrens-Baumann W; Ohrloff C
    Retina; 2009; 29(7):932-40. PubMed ID: 19584651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits.
    Ameri H; Kim JG; Ratanapakorn T; Chader GJ; Humayun MS
    Retina; 2008 Feb; 28(2):350-5. PubMed ID: 18301042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
    Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K
    Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experiment study of infusing tPA in retinal vein for treatment of retinal vein occlusion].
    Hu YT; Ma ZZ; Zhang XL; Han SY; Huang LJ
    Zhonghua Yan Ke Za Zhi; 2003 Nov; 39(11):645-9. PubMed ID: 14766057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion.
    Hattenbach LO; Kuhli-Hattenbach C; Scharrer I; Baatz H
    Am J Ophthalmol; 2008 Nov; 146(5):700-6. PubMed ID: 18718570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mutalysin II on vascular recanalization after thrombosis induction in the ear of the hairless mice model.
    Agero U; Arantes RM; Lacerda-Queiroz N; Mesquita ON; Magalhães A; Sanchez EF; Carvalho-Tavares J
    Toxicon; 2007 Oct; 50(5):698-706. PubMed ID: 17681580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion.
    Oncel M; Peyman GA; Khoobehi B
    Retina; 1989; 9(1):1-7. PubMed ID: 2497501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental retinal vein occlusion induced by photodynamic approach].
    Zhang XL; Hu YT; Ma ZZ; Wang CG; Han SY; Yang BJ; Huang LJ
    Zhonghua Yan Ke Za Zhi; 2003 Apr; 39(4):220-3. PubMed ID: 12882700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental endoscopic endovascular cannulation: a novel approach to thrombolysis in retinal vessel occlusion.
    Hattenbach LO; Puchta J; Hilgenberg I
    Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):42-6. PubMed ID: 22131392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.
    Lahey JM; Fong DS; Kearney J
    Ophthalmic Surg Lasers; 1999 Jun; 30(6):427-34. PubMed ID: 10392729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study.
    Feltgen N; Junker B; Agostini H; Hansen LL
    Ophthalmology; 2007 Apr; 114(4):716-23. PubMed ID: 17141322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct continuous observation of in situ thrombolysis in the cerebral embolic model of rabbits].
    Kashiwabara S; Kurokawa Y; Uede T; Hashi K
    No To Shinkei; 1998 Apr; 50(4):347-54. PubMed ID: 9592824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion.
    Weizer JS; Fekrat S
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):350-2. PubMed ID: 12875471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ultrasound-assisted thrombolysis using custom liposomes in a model of retinal vein occlusion.
    Abdallah WF; Patel H; Grant EG; Diniz B; Chader GJ; Humayun MS
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6920-7. PubMed ID: 22969076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.